Zydus Cadila has received the final approval from the USFDA to market Piroxicam Capsules USP (US RLD-Feldene Capsules) in strengths of 10 mg and 20 mg.

It is a non-steroidal anti-inflammatory drug indicated for symptomatic treatment of osteoarthritis and rheumatoid arthritis. It will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.

In line with this, the group now has 209 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company declined Rs 4.75, or 1.34%, to trade at Rs 349.35. The total volume of shares traded was 15,752 at the BSE (10.11 a.m., Thursday).